SynthesisScientific reports2025
Clinical and laboratory characteristics of novel diabetes subgroups: A systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proper classification of diabetes enhances accurate diagnosis and tailored management, and recent researchers introduce an innovative subgroup classification for adult diabetes. This study aims to evaluate the attributes of these novel diabetes subgroups. We conducted a systematic search across MEDLINE, Embase, and the Cochrane Library, focusing on the characteristics of novel diabetes subgroups. These included mild age-related diabetes (MARD), mild obesity-related diabetes (MOD), severe insulin-resistant diabetes (SIRD), severe insulin-deficient diabetes (SIDD), severe autoimmune diabetes (SAID), severe insulin-deficient and insulin-resistant diabetes (SIDRD), and severe obesity-related and insulin-resistant diabetes (SOIRD). Our review included 19 studies comprising 59,915 cases: 2,603 (4.34%) SAID, 14,946 (25.94%) SIDD, 9,285 (15.50%) SIRD, 13,323 (22.24%) MOD, 19,465 (32.49%) MARD, 87 (0.15%) SIDRD, and 206 (0.34%) SOIRD cases. The SIDD subgroup exhibited a reduced homeostatic model assessment of β-cell function. Both SIDRD and SIDD subgroups demonstrated elevated levels of HbA1c. Subgroups SIRD and MARD had decreased eGFR levels, correlating with a higher incidence of nephropathy. The SIRD subgroup presented the most significantly altered lipid metabolism and the highest insulin resistance. Distinct clinical and laboratory characteristics among the diabetes subgroups reveal the necessity for diverse treatment strategies. Tailored approaches are essential to effectively manage the various diabetes subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.